Maintenance DFMO Increases Survival in High Risk Neuroblastoma.
Publication/Presentation Date
9-27-2018
Abstract
High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent relapse following completion of standard therapy (Stratum 1) or after salvage therapy for relapsed/refractory disease (Stratum 2). This Phase II single agent, single arm multicenter study enrolled from June 2012 to February 2016. Subjects received 2 years of oral DFMO (750 ± 250 mg/m
Volume
8
Issue
1
First Page
14445
Last Page
14445
ISSN
2045-2322
Published In/Presented At
Sholler, G. L. S., Ferguson, W., Bergendahl, G., Bond, J. P., Neville, K., Eslin, D., Brown, V., Roberts, W., Wada, R. K., Oesterheld, J., Mitchell, D., Foley, J., Parikh, N. S., Eshun, F., Zage, P., Rawwas, J., Sencer, S., Pankiewicz, D., Quinn, M., Rich, M., … Kraveka, J. M. (2018). Maintenance DFMO Increases Survival in High Risk Neuroblastoma. Scientific reports, 8(1), 14445. https://doi.org/10.1038/s41598-018-32659-w
Disciplines
Medicine and Health Sciences | Pediatrics
PubMedID
30262852
Department(s)
Department of Pediatrics
Document Type
Article